5-Amino-1MQ – Technical Brief (For Research-Use-Only)
1. Identity
5-Amino-1MQ is a small molecule drug designed to inhibit nicotinamide N-methyltransferase (NNMT), an enzyme involved in fat metabolism and cellular energy regulation. It has gained attention for its potential role in weight management, metabolic health, and anti-aging.
2. Mechanism of Action
5-Amino-1MQ works by:
- Inhibiting NNMT: Reduces fat accumulation and enhances metabolic efficiency.
- Increasing NAD+ levels: Supports cellular energy production and longevity.
- Activating SIRT1 (the "longevity gene"): Enhances mitochondrial function and fat oxidation.
3. Uses
5-Amino-1MQ is primarily researched for:
- Weight loss and fat metabolism: May promote fat burning while preserving muscle mass.
- Metabolic health: Investigated for its role in improving insulin sensitivity and lipid profiles.
- Anti-aging and longevity: Potential applications in cellular regeneration and mitochondrial health.
- Cancer research: Some studies suggest it may disrupt energy supply to cancer cells.
4. Dosage
Common research protocols include:
- General use: 50–300mcg per day, divided into 1–3 doses.
- Weight loss applications: 150–300mcg per day.
- Research studies: 150–300mcg/kg/day, depending on protocol.
- Administration: Subcutaneous injections with insulin syringe
5. Safety Profile
- Common side effects: Mild headaches, occasional gastrointestinal discomfort.
- Precautions: Limited human data; long-term effects require further study.
- No known toxicity: Generally well-tolerated in research settings.
6. Storage Guidelines
- Before use: Store in a cool, dry place, protected from light.
- Reconstitution: If using an injectable form, mix with bacteriostatic water.
- Do not freeze: Freezing reconstituted vials may degrade the compound’s integrity.
7. Legality in the UK
5-Amino-1MQ is not approved for human consumption in the UK and is classified as a research chemical. It is available for scientific studies but cannot be legally marketed or sold for human use. Regulatory bodies such as the MHRA (Medicines and Healthcare products Regulatory Agency) have not authorized it for medical applications.
